Literature DB >> 15757967

Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

Sònia Jiménez1, M Angels García-Criado, Dolors Tàssies, Joan Carles Reverter, Ricard Cervera, M Rosa Gilabert, Daniel Zambón, Emilio Ros, Concepció Bru, Josep Font.   

Abstract

OBJECTIVE: To determine the prevalence of preclinical vascular disease and associated risk factors in patients with systemic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS).
METHODS: We consecutively studied 70 SLE patients and 25 primary APS patients without clinical coronary artery disease. The control group included 40 healthy women. Carotid ultrasound was performed and the intima-media wall thickness (IMT) and presence of plaque was investigated in all patients and controls. Traditional vascular risk factors and SLE-disease and treatment related factors were also analysed.
RESULTS: SLE patients had a higher prevalence of traditional atherosclerosis risk factors: hypertension (P<0.005) and dyslipidaemia (P<0.05) and higher levels of total cholesterol (P = 0.03), triglycerides (P = 0.004) and apolipoprotein B (P = 0.04). The prevalence of carotid plaque was higher and appeared earlier in SLE patients than in the primary APS patients or controls (P<0.001). The IMT was similar in the three groups. SLE patients with secondary APS had a higher prevalence of carotid plaque than patients with primary APS (37.5% vs 8%, P = 0.03). The presence of plaque in SLE patients was associated with a higher SLICC score (2.40 +/- 1.78 vs 1.02 +/- 1.18, P = 0.002), higher ECLAM score (3.10 +/- 2.32 vs 1.84 +/- 1.59, P = 0.02) and older age (47.3 +/- 8.44 vs 37.38 +/- 11.28, P = 0.003) at the time of carotid ultrasound study.
CONCLUSION: Plaque prevalence in patients with primary APS is similar to that of controls and inferior to that of SLE patients with secondary APS. SLE patients have a high prevalence of early carotid atherosclerosis that is associated with cumulative disease damage and disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757967     DOI: 10.1093/rheumatology/keh581

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  23 in total

1.  Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Authors:  Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight
Journal:  Ann Rheum Dis       Date:  2016-07-18       Impact factor: 19.103

2.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

3.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

4.  Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala.

Authors:  Shajit Sadanand; Binoy J Paul; Emil J Thachil; Rejadheesh Meletath
Journal:  Eur J Rheumatol       Date:  2016-12-01

5.  Abdominal pain in patient with antiphospholipid syndrome-the role of MDCT angiography on visceral blood vessels.

Authors:  Jovica Saponjski; Ljudmila Stojanovich; Jelena Saponjski; Milorad Mirilovic; Dusan Saponjski
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

6.  Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus.

Authors:  D K Wells; M M Ward
Journal:  Clin Exp Rheumatol       Date:  2010-05-13       Impact factor: 4.473

7.  Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus.

Authors:  Luísa Lima Castro; Cristina Costa Duarte Lanna; Antônio Luiz Pinho Ribeiro; Rosa Weiss Telles
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

8.  Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study.

Authors:  Carlos A Roldan; Joseph Joson; Janeen Sharrar; Clifford R Qualls; Wilmer L Sibbitt
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

Review 9.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

10.  Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes?

Authors:  Aleksandra Djokovic; Lj Stojanovich; N Stanisavljevic; V Bisenic; S Radovanovic; I Soldatovic; D V Simic
Journal:  Rheumatol Int       Date:  2013-11-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.